Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma.
2/5 보강
TL;DR
It is identified that NSUN4, an m5C methyltransferase, is highly expressed not only in the venetoclax-resistant cell line but also in the lymph nodes of recurrent and refractory DLBCL patients primarily by inhibiting the p53 signaling pathway, although the precise mechanism warrants further investigation.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: recurrent and refractory diffuse large B-cell lymphoma (DLBCL) exhibit high levels of BCL-2 expression
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Understanding how m5C methylation mediates venetoclax resistance and regulates the p53 pathway will provide a theoretical foundation for overcoming venetoclax resistance in patients with recurrent and refractory DLBCL. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10238-026-02117-3.
OpenAlex 토픽 ·
Protein Degradation and Inhibitors
Lymphoma Diagnosis and Treatment
RNA modifications and cancer
It is identified that NSUN4, an m5C methyltransferase, is highly expressed not only in the venetoclax-resistant cell line but also in the lymph nodes of recurrent and refractory DLBCL patients primari
APA
Yuanfei Shi, Heli Wen, et al. (2026). Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma.. Clinical and experimental medicine, 26(1). https://doi.org/10.1007/s10238-026-02117-3
MLA
Yuanfei Shi, et al.. "Effects and molecular mechanism of inhibiting p53 signaling pathway by NSUN4 on the resistance to BCL-2 inhibitor for diffuse large B-cell lymphoma.." Clinical and experimental medicine, vol. 26, no. 1, 2026.
PMID
41865121 ↗
Abstract 한글 요약
[UNLABELLED] A significant proportion of patients with recurrent and refractory diffuse large B-cell lymphoma (DLBCL) exhibit high levels of BCL-2 expression. However, some of these patients are resistant to BCL-2 inhibitors, and the underlying mechanisms remain unclear. In venetoclax-resistant DLBCL cell line, a Cell Counting Kit-8 (CCK8) assay was used to determine the half-maximal inhibitory concentration (IC) value. Flow cytometric was performed to determine mitochondrial membrane potential (MMP), reactive oxygen species (ROS), and cell apoptosis rates, respectively. The construction of NSUN4 knockdown/overexpression cell line using CRISPR-Cas9 technology. KEGG pathway enrichment analysis indicated that NSUN4 modulates venetoclax resistance. Furthermore, we used Western blotting to explore the mechanism underlying venetoclax-resistant. Finally, the antileukemic activity was further evaluated in an in vivo xenograft model. We identified that NSUN4, an m5C methyltransferase, is highly expressed not only in the venetoclax-resistant cell line but also in the lymph nodes of recurrent and refractory DLBCL patients primarily by inhibiting the p53 signaling pathway, although the precise mechanism warrants further investigation, and is correlated with poor prognosis. Moreover, we discovered that Apatinib could reduce NSUN4 expression and effectively reverse venetoclax resistance. These findings suggest that NSUN4 is a critical target for overcoming venetoclax resistance in DLBCL patients. Our study reveals the role of NSUN4 and the p53 signaling pathway in venetoclax resistance at the molecular, cellular, and animal levels. Understanding how m5C methylation mediates venetoclax resistance and regulates the p53 pathway will provide a theoretical foundation for overcoming venetoclax resistance in patients with recurrent and refractory DLBCL.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10238-026-02117-3.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s10238-026-02117-3.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- T cell-intrinsic PRR signaling in immunity and pathology.
- Correction: RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression.
- Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies.
- Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021.
- Prognostic significance of POD24 in primary central nervous system diffuse large B-cell lymphoma: a retrospective study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.
- Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
- Prognostic Value of the CALLY Index in Diffuse Large B-Cell Lymphoma: Linking Inflammation, Nutrition, and Tumor Biology.
- Survival outcomes and treatment patterns in primary vertebral diffuse large B-cell lymphoma.